Company Overview of Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc., a biopharmaceutical company, develops treatments to optimize therapeutic benefits and reduce adverse effects for chronic and life-threatening diseases. The company offers ITCA 650 for the treatment of type 2 diabetes by using its subcutaneous delivery system (its technology platform), which is a matchstick-sized device, including a cylindrical titanium alloy reservoir that is inserted under the skin to allow the water from the extracellular fluid to enter the device at one end by diffusing through a semi-permeable membrane directly into a salt osmotic engine that expands to drive a piston at a controlled rate of travel, and forces the drug formulation to be relea...
155 Seaport Boulevard
Boston, MA 02210
Founded in 1995
Key Executives for Intarcia Therapeutics, Inc.
Executive Chairman, Chief Executive Officer and President
Chief Financial Officer and Vice President of Finance & Operations
Chief Legal Officer, Vice President and General Counsel
Chief Business Officer and Head of Corporate Development
Vice President of Development & Manufacturing
Compensation as of Fiscal Year 2014.
Intarcia Therapeutics, Inc. Key Developments
Intarcia Therapeutics, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 11:30 AM
Jan 6 15
Intarcia Therapeutics, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 11:30 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Kurt C. Graves, Executive Chairman, Chief Executive Officer and President.
Intarcia Therapeutics, Inc., Servier Sign Ex-US Partnership for ITCA 650 in Diabetes
Nov 11 14
Intarcia Therapeutics, Inc. on November 11, 2014 announced the successful start of a strategic partnership with Servier outside the United States and Japan, to develop and commercialize ITCA 650, Intarcia's phase 3 investigational therapy for the treatment of type 2 diabetes. If successful in its remaining phase 3 trials, ITCA 650 would become the world's first and only injection-free GLP-1 agonist given just once or twice yearly in a small, matchstick sized mini-pump placed sub-dermally. A qualified physician, nurse or physician's assistant can place ITCA 650 in a simple five-minute procedure in a doctor's office. Under the agreement, Intarcia is to receive an upfront payment and total potential development, regulatory and sales milestone payments totaling more than $1 billion. Intarcia will also receive ex-U.S./Japan tiered sales-related payments. The parties will also share future global development-related investments for the life cycle management of ITCA 650, including new head-to-head superiority studies against leading diabetes medications, as well as planned novel combination regimens. Intarcia will continue to lead the global ITCA 650 phase 3 pivotal trials, which are on track to support global filings in the first half of 2016. Intarcia also will continue its lead role in the potential registration of ITCA 650 in the U.S., while Servier will seek regulatory approvals outside the U.S. and Japan, with the support of Intarcia.
Intarcia Therapeutics, Inc. Announces the Positive Interim Clinical Data of Phase 3 Data at EASD
Sep 19 14
Intarcia Therapeutics, Inc. announced the positive interim clinical data for it’s lead candidate ITCA 650 (continuous subcutaneous delivery of exenatide) in type 2 diabetes patients with high baseline HbA1c levels at the 50(th) Annual Meeting of the European Association for the Study of Diabetes (EASD). Data from the open-label, phase 3 FREEDOM-HBL (high baseline) trial showed markedly reduced levels of blood sugar in patients with poorly controlled type 2 diabetes. The overall results from the full 9-month HBL study and the FREEDOM-1 trial are expected to be announced in the fourth quarter of 2014. The results and conclusions are FREEDOM-1 is a double-blind, randomized, placebo-controlled, multicenter study to evaluate the efficacy and safety of ITCA 650 in type 2 diabetes patients with an HbA1c between 7.5% and 10.0; Patients who met all inclusion criteria for FREEDOM-1 but had HbA1c greater than or equal to 10% but less than or equal to 12% were enrolled in FREEDOM-HBL; On average, patients enrolled to FREEDOM-HBL had been diagnosed with T2D for 9 years and a majority was being treated with multiple background oral anti-diabetes therapies; enrolling patients with high baseline HbA1c provides a robust opportunity; o evaluate treatment response in a poorly controlled patient population. In this interim analysis, the addition of ITCA 650 resulted in mean HbA1c reductions greater than 3% in patients who reached 6 months of treatment. 30% of patients who reached 13 weeks of treatment (n=50) achieved the target HbA1c of less than 7%. ITCA 650 treatment was also accompanied by weight loss, which is not commonly observed in the treatment of patients with high baseline HbA1c. ITCA 650 has the potential to markedly improve glycemic control patients with severe hyperglycemia and longstanding diabetes. ITCA 650 may offer potential benefits over existing oral and injectable therapies for type 2 diabetes via sustained glycemic control, favorableweight profile, improved tolerability, ensured adherence with once- or twice-yearly dosing, and no injections.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|